INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo
Executive Summary
Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark
You may also be interested in...
Pharmasset Casts Wide Phase III Net With Interferon-Free, Two-Drug Combo
Phase II ELECTRON study yielded 100% cure rate across all arms, including interferon-sparing and interferon-free regimens.
Boehringer Ingelheim's Phase II Agent Could Be The First Second-Wave Protease Inhibitor For Hep C
BI's '355 has impressive response rates in early studies, but jaundice is a concern.
Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD
Next-generation ritonavir-boosted protease inhibitor is headed into Phase IIb, and if all goes well, could be a significant player in the hepatitis C market.